Tradename: BALFAXAR
Proper Name: prothrombin complex concentrate, human-lans
Indication: Indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for an urgent surgery/invasive procedure.
Approval Date: 07/21/2023
Manufacturer: Octapharma USA, Inc.
More: https://www.fda.gov/vaccines-blood-biologics/balfaxar